Still grappling with its towering debt, Valeant Pharmaceuticals International Inc. on Tuesday focused on promoting several new consumer health products that the company hopes will reinvigorate its shrunken cash flows.
Management at the Laval, Quebec-based company have been undergoing a dramatic restructuring of the company following a product pricing scandal, selling billions in assets and tightening its focus on a few select segments of the business.
The corporate makeover has in turn placed pressure on management to provide new consumer products that will generate fresh revenue streams, giving the company space to reduce its debt obligations.
As we think about the future the very clear direction we have is going to be to…
Read the full article at: http://business.financialpost.com/investing/valeant-cuts-revenue-forecast-expects-to-repay-more-than-5-billion-in-debt/wcm/5ed639ae-c698-4e3a-9d81-6fb2f73579f6